Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Published

Journal Article (Review)

Hepatitis C virus (HCV) represents a significant global disease burden, with an estimated 130-150 million people worldwide living with chronic HCV infection. Within the six major clinical HCV genotypes, genotype 3 represents 22-30% of all infection and is described as a unique entity with higher rates of steatosis, faster progression to cirrhosis, and higher rates of hepatocellular carcinoma. Hepatic steatosis in the setting of hepatitis C genotype 3 (HCV-3) is driven by viral influence on three major pathways: microsomal triglyceride transfer protein, sterol regulatory element-binding protein-1c, and peroxisome proliferator-associated receptor-α. Historically with direct-acting antivirals, the rates of cure for HCV-3 therapies lagged behind the other genotypes. As current therapies for HCV-3 continue to close this gap, it is important to be cognizant of common drug interactions such as acid-suppressing medication and amiodarone. In this review, we discuss the rates of steatosis in HCV-3, the mechanisms behind HCV-3-specific steatosis, and current and future therapies.

Full Text

Duke Authors

Cited Authors

  • Chan, A; Patel, K; Naggie, S

Published Date

  • February 2017

Published In

Volume / Issue

  • 77 / 2

Start / End Page

  • 131 - 144

PubMed ID

  • 28074358

Pubmed Central ID

  • 28074358

Electronic International Standard Serial Number (EISSN)

  • 1179-1950

International Standard Serial Number (ISSN)

  • 0012-6667

Digital Object Identifier (DOI)

  • 10.1007/s40265-016-0685-x

Language

  • eng